TG Therapeutics | TGTX - Selling And Administration Expenses


TG Therapeutics reported $73.14M in Selling and Administration Expenses for its fiscal quarter ending in March of 2026.





Selling And Administration Expenses Change Date
AbbVie USD 3.58B 316M Mar/2026
Alaunos Therapeutics USD 447K 138K Mar/2026
Amgen USD 1.58B 354M Mar/2026
Ardelyx USD 75.92M 7.69M Dec/2025
Arrowhead Research USD 41.74M 4.28M Mar/2026
Bayer EUR 3.7B 356M Mar/2026
Biogen USD 554.3M 128.2M Mar/2026
Corcept Therapeutics USD 128.04M 13.3M Mar/2026
Curis USD 1.34M 3.45M Dec/2025
Gilead Sciences USD 1.45B 326M Mar/2026
J&J USD 6.03B 719M Mar/2026
Karyopharm Therapeutics USD 9.56M 17.63M Dec/2025
Novartis USD 3.14B 296M Mar/2026
Novavax USD 25.53M 1.34M Dec/2025
PTC Therapeutics USD 73.89M 13.31M Mar/2026
Puma Biotechnology USD 16.82M 8.15M Sep/2024
Regeneron Pharmaceuticals USD 647.7M 127.3M Mar/2026
Roche Holding CHF 7.28B 3.99B Dec/2025
TG Therapeutics USD 73.14M 22.42M Mar/2026
Verastem USD 24.44M 12.17M Dec/2025
Vertex Pharmaceuticals USD 493.7M 6.7M Mar/2026